Literature DB >> 26216017

The importance of the 6- and 7-positions of tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

David A Perrey1, Ann M Decker1, Jun-Xu Li2, Brian P Gilmour1, Brian F Thomas1, Danni L Harris1, Scott P Runyon1, Yanan Zhang3.   

Abstract

Selective antagonism of the orexin 1 (OX1) receptor has been proposed as a potential mechanism for treatment of drug addiction. We have previously reported studies on the structure-activity relationships of tetrahydroisoquinoline-based antagonists. In this report, we elucidated the respective role of the 6- and 7-substitutions by preparation of a series of either 6-substituted tetrahydroisoquinolines (with no 7-substituents) or vice versa. We found that 7-substituted tetrahydroisoquinolines showed potent antagonism of OX1, indicating that the 7-position is important for OX1 antagonism (10 c, Ke = 23.7 nM). While the 6-substituted analogs were generally inactive, several 6-amino compounds bearing ester groups showed reasonable potency (26 a, Ke = 427 nM). Further, we show evidence that suggests several compounds initially displaying insurmountable antagonism at the OX1 receptor are competitive antagonists with slow dissociation rates.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antagonist; Orexin; Selective; Tetrahydroisoquinoline

Mesh:

Substances:

Year:  2015        PMID: 26216017      PMCID: PMC4554834          DOI: 10.1016/j.bmc.2015.07.013

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  33 in total

Review 1.  Orexin receptor antagonists: a new concept in CNS disorders?

Authors:  John Gatfield; Catherine Brisbare-Roch; Francois Jenck; Christoph Boss
Journal:  ChemMedChem       Date:  2010-08-02       Impact factor: 3.466

2.  Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement.

Authors:  James R Shoblock; Natalie Welty; Leah Aluisio; Ian Fraser; S Timothy Motley; Kirsten Morton; James Palmer; Pascal Bonaventure; Nicholas I Carruthers; Timothy W Lovenberg; Jamin Boggs; Ruggero Galici
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

Review 3.  [Orexin].

Authors:  Takeshi Sakurai
Journal:  Nihon Rinsho       Date:  2005-08

Review 4.  Selective orexin receptor antagonists.

Authors:  Terry P Lebold; Pascal Bonaventure; Brock T Shireman
Journal:  Bioorg Med Chem Lett       Date:  2013-07-04       Impact factor: 2.823

5.  Effect of 1-substitution on tetrahydroisoquinolines as selective antagonists for the orexin-1 receptor.

Authors:  David A Perrey; Nadezhda A German; Ann M Decker; David Thorn; Jun-Xu Li; Brian P Gilmour; Brian F Thomas; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2015-02-12       Impact factor: 4.418

Review 6.  Multiple roles for orexin/hypocretin in addiction.

Authors:  Stephen V Mahler; Rachel J Smith; David E Moorman; Gregory C Sartor; Gary Aston-Jones
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 7.  Role of orexin/hypocretin in dependence and addiction.

Authors:  Ruth Sharf; Maysa Sarhan; Ralph J Dileone
Journal:  Brain Res       Date:  2009-08-20       Impact factor: 3.252

8.  Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.

Authors:  Pari Malherbe; Edilio Borroni; Emmanuel Pinard; Joseph G Wettstein; Frédéric Knoflach
Journal:  Mol Pharmacol       Date:  2009-06-19       Impact factor: 4.436

Review 9.  Suvorexant: first global approval.

Authors:  Lily P H Yang
Journal:  Drugs       Date:  2014-10       Impact factor: 9.546

10.  Substituted tetrahydroisoquinolines as selective antagonists for the orexin 1 receptor.

Authors:  David A Perrey; Nadezhda A German; Brian P Gilmour; Jun-Xu Li; Danni L Harris; Brian F Thomas; Yanan Zhang
Journal:  J Med Chem       Date:  2013-08-26       Impact factor: 7.446

View more
  6 in total

1.  Discovery of Novel Proline-Based Neuropeptide FF Receptor Antagonists.

Authors:  Thuy Nguyen; Ann M Decker; Tiffany L Langston; Kelly M Mathews; Justin N Siemian; Jun-Xu Li; Danni L Harris; Scott P Runyon; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-08-09       Impact factor: 4.418

2.  Structure-based development of a subtype-selective orexin 1 receptor antagonist.

Authors:  Jan Hellmann; Matthäus Drabek; Jie Yin; Jakub Gunera; Theresa Pröll; Frank Kraus; Christopher J Langmead; Harald Hübner; Dorothee Weikert; Peter Kolb; Daniel M Rosenbaum; Peter Gmeiner
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-15       Impact factor: 11.205

3.  Hypocretin receptor 1 blockade produces bimodal modulation of cocaine-associated mesolimbic dopamine signaling.

Authors:  K A Levy; Z D Brodnik; J K Shaw; D A Perrey; Y Zhang; R A España
Journal:  Psychopharmacology (Berl)       Date:  2017-06-30       Impact factor: 4.530

4.  Synthesis and Evaluation of Orexin-1 Receptor Antagonists with Improved Solubility and CNS Permeability.

Authors:  David A Perrey; Ann M Decker; Yanan Zhang
Journal:  ACS Chem Neurosci       Date:  2017-11-20       Impact factor: 4.418

5.  Magnesium-Promoted Additions of Difluoroenolates to Unactivated Imines.

Authors:  Alex L Nguyen; Hari R Khatri; James R Woods; Cassidy S Baldwin; Frank R Fronczek; David A Colby
Journal:  J Org Chem       Date:  2018-02-27       Impact factor: 4.354

Review 6.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.